+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cell and Gene Therapy Market - Global Outlook and Forecast 2019-2024

  • ID: 4856594
  • Report
  • November 2019
  • Region: Global
  • 256 pages
  • Arizton
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Amgen
  • Biosolution
  • Corestem
  • JCR Pharmaceuticals
  • Novartis AG
  • Spark Therapeutics
  • MORE
The global cell and gene therapy market is growing at a CAGR of over 24% during the forecast period 2018–2024.

The major drivers contributing to the growth of the global cell and gene therapy market are the growing incidence of several chronic and terminal diseases, including cancer, the launch of new products, the increasing availability in clinical evidences of these products in terms of safety and efficacy, the rapid adoption of CAR T-cell therapy, favorable regulatory support in the development of these treatment, and improved manufacturing expertise in these products.

The following factors are likely to contribute to the growth of the cell and gene therapy market during the forecast period:
  • Increased Pool of Patient Population with Several Ailments
  • Favorable Regulatory Support and Increasing Special Designations for Cell and Gene Therapy Products
  • Growing Demand for CAR T-cell Therapy Products
  • Increasing Strategic Acquisition Activities
The study considers the present scenario of the cell and gene therapy market and its market dynamics for the period 2018−2024. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply aspects of the market. The report profiles and examines leading companies and other prominent companies operating in the market.

Cell and Gene Therapy Market: Segmentation

This research report includes detailed market segmentation by product, application, end-user, and geography. The global cell therapy market is growing at a steady rate, and this trend is expected to continue during the forecast period due to the increased patient base with a wide range of diseases/ailments. The segment is likely to witness upward growth on account of expanded expertise in the manufacturing of stem cell-based products.

The gene therapy segment is expected to witness faster growth as the penetration of these products is increasing at a significant rate, especially in developed economies. The market is expected to grow during the forecast period due to the increased patient base for the existing gene remedy products, expected the launch of other gene therapy-based products for several indications, and expanded indication approvals for existing commercially available products.

The oncology segment accounts for the highest share of the global market. The growth of the oncology segment is increasing at a fast rate on account of the growing prevalence of several types of cancers. Currently, the available products not only modify the disease but also improve the quality of the patient’s life, thereby decreasing the mortality rate. The market in the dermatology segment is increasing at a steady rate. This segment owns its growth to the increasing incidence and prevalence rate of several types of wounds, which are difficult to treat under normal conditions and the launch of innovative products. The dermatology segment is likely to showcase growth due to the high product availability of wound care products in the market.

Hospitals are the leading end-user segment. The segment is growing mainly due to the increasing incidence/prevalence of chronic diseases such as cancer, cardiovascular diseases, diabetes, and chronic wound on account of diabetes feet, pressure ulcers, and other injuries.

Market Segmentation by Products
  • Cell Therapy
  • Gene Therapy
Market Segmentation by Distribution Channel Type
  • Oncology
  • Dermatology
  • Musculoskeletal
  • Others
Market Segmentation by End-users
  • Hospitals
  • Wound Care Centers
  • Cancer Care Centers
  • Ambulatory Surgical Centers
  • Others
Geographical Insights

The US market dominates the cell and gene therapy market in North America due to the high prevalence of chronic diseases and other conditions, which require these treatment methods. There is also comparably high utilization and wide accessibility of these therapies. The oncology segment is likely to witness significant growth in North America.
The market in Europe is expected to witness upward growth in the near future on account of the growing prevalence of chronic diseases and rising elderly population. In Europe, cell and gene therapy products are considered to be part of the Advanced Therapy Medicinal Products (ATMPs), which are commonly known as regenerative medicine globally.

Market Segmentation by Geography
  • North America
  • US
  • Canada
  • APAC
  • Japan
  • China
  • South Korea
  • Australia
  • Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Latin America
  • Brazil
  • Mexico
  • MEA
  • Turkey
  • Saudi Arabia
  • UAE
Key Vendor Analysis

The global market is characterized by the presence of a few global, large-scale companies and several small to medium-scale companies offering one or two cell and gene therapy products. Global players are majorly offering innovative products with the potential of disease-modifying characteristics that are generating significant revenues, especially in Europe and US regions. Most innovative and breakthrough products are approved in the European countries and the US. Vendors are targeting mostly developed economies such as the US, Germany, France, the UK, Spain, and Japan as the uptake of these products is higher in these countries than low and middle-income countries. However, the market in these regions is at the nascent stage.

Key Vendors
  • Gilead Sciences
  • Spark Therapeutics
  • Novartis AG
  • Organogenesis
  • Amgen
  • Osiris Therapeutics
  • Dendreon
  • Vericel
Other Prominent Vendors
  • Anterogen
  • Tego Sciences
  • Japan Tissue Engineering
  • JCR Pharmaceuticals
  • Medipost
  • MolMed
  • AVITA Medical
  • CollPlant
  • Corestem
  • Biosolution
  • Stempeutics Research
  • Orchard Therapeutics
  • Takeda Pharmaceutical Company
  • CHIESI Farmaceutici
  • CO.DON
  • AnGes
  • GC Pharma
  • JW CreaGene
  • APAC Biotech
  • Nipro Corp.
  • Terumo
  • Orthocell
  • bluebird bio
Key Market Insights

The report provides the following insights into the market for the forecast period 2019–2024.
  • Offers sizing and growth prospects of the market for the forecast period 2019–2024.
  • Provides comprehensive insights on the latest industry trends, forecast, and growth drivers in the market.
  • Includes a detailed analysis of growth drivers, challenges, and investment opportunities.
  • Delivers a complete overview of segments and the regional outlook of the market.
  • Offers an exhaustive summary of the vendor landscape, competitive analysis, and key strategies to gain a competitive advantage.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen
  • Biosolution
  • Corestem
  • JCR Pharmaceuticals
  • Novartis AG
  • Spark Therapeutics
  • MORE
1 Research Methodology

2 Research Objectives

3 Research Process

4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope of the study
4.4 Market Segments
4.4.1 Market Segmentation by Products
4.4.2 Market Segmentation by Applications
4.4.3 Market Segmentation by End-users
4.4.4 Market Segmentation by Geography

5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation

6 Market at a Glance
7 Introduction
7.1 Overview
7.2 Cell and Gene Therapy: An Overview

8 Market Dynamics
8.1 Market Growth Enablers
8.1.1 Increased Pool of Patients with Various Diseases
8.1.2 Product Launches and Approvals
8.1.3 Favorable Regulatory Support and Special Designations for Cell and Gene Therapy Products
8.1.4 Growing Demand for CAR T-cell Therapy Products
8.2 Market Growth Restraints
8.2.1 High Cost of Cell and Gene Therapy Products
8.2.2 Manufacturing and Operational Challenges
8.2.3 Availability of Alternate Treatments and Withdrawal of Products
8.3 Market Opportunities and Trends
8.3.1 Increasing Strategic Acquisition Activities
8.3.2 Robust Cell and Gene Therapy Pipeline Products
8.3.3 Increasing Funding for Cell and Gene Therapy R&D Activities
8.3.4 Expanding Application of Cell and Gene Therapy Products

9 Global Cell & Gene Therapy Market
9.1 Market Overview
9.2 Market Size & Forecast
9.2.1 By Geography
9.2.2 By Product
9.2.3 By Application
9.2.4 By End-user
9.3 Five Forces Analysis
9.3.1 Threat of New Entrants
9.3.2 Bargaining Power of Suppliers
9.3.3 Bargaining Power of Buyers
9.3.4 Threat of Substitutes
9.3.5 Competitive Rivalry

10 By Product
10.1 Market Snapshot & Growth Engine
10.2 Market Overview
10.3 Cell Therapy
10.3.1 Market Overview
10.3.2 Market Size & Forecast
10.4 Gene Therapy
10.4.1 Market Overview
10.4.2 Market Size & Forecast

11 By Application
11.1 Market Snapshot & Growth Engine
11.2 Market Overview
11.3 Oncology
11.3.1 Market Overview
11.3.2 Market Size & Forecast
11.4 Dermatology
11.4.1 Market Overview
11.4.2 Market Size & Forecast
11.5 Musculoskeletal
11.5.1 Market Overview
11.5.2 Market Size & Forecast
11.6 Others
11.6.1 Market Overview
11.6.2 Market Size & Forecast

12 By End-User
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Hospitals
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.4 Wound Care Centers
12.4.1 Market Overview
12.4.2 Market Size & Forecast
12.5 Cancer Care Centers
12.5.1 Market Overview
12.5.2 Market Size & Forecast
12.6 Ambulatory surgical centers (ASC)
12.6.1 Market Overview
12.6.2 Market Size & Forecast
12.7 Others
12.7.1 Market Overview
12.7.2 Market Size & Forecast

13 By Geography
13.1 Market Snapshot & Growth Engine
13.2 Market Overview

14 North America
14.1 Market Overview
14.2 Market Size & Forecast
14.3 Key Countries
14.3.1 US: Market Size & Forecast
14.3.2 Canada: Market Size & Forecast

15 Europe
15.1 Market Overview
15.2 Market Size & Forecast
15.3 Key Countries
15.3.1 Germany: Market Size & Forecast
15.3.2 France: Market Size & Forecast
15.3.3 UK: Market Size & Forecast
15.3.4 Spain: Market Size & Forecast
15.3.5 Italy: Market Size & Forecast

16 APAC
16.1 Market Overview
16.2 Market Size & Forecast
16.3 Key Countries
16.3.1 Japan: Market Size & Forecast
16.3.2 China: Market Size & Forecast
16.3.3 South Korea: Market Size & Forecast
16.3.4 Australia: Market Size & Forecast

17 Latin America
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Key Countries
17.3.1 Brazil: Market Size & Forecast
17.3.2 Mexico: Market Size & Forecast

18 Middle East & Africa
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Key Countries
18.3.1 Turkey: Market Size & Forecast
18.3.2 Saudi Arabia: Market Size & Forecast
18.3.3 UAE: Market Size & Forecast

19 Competitive Landscape
19.1 Competition Overview
19.2 Market Share Analysis
19.2.1 Cell Therapy
19.2.2 Gene Therapy

20 Key Company Profiles
20.1 Gilead Sciences
20.1.1 Business Overview
20.1.2 Gilead Sciences in Global Cell and Gene Therapy
20.1.3 Major Product Offerings
20.1.4 Key Strengths
20.1.5 Key Strategies
20.1.6 Key Opportunities
20.2 Spark Therapeutics
20.2.1 Business Overview
20.2.2 Spark Therapeutics in Cell and Gene Therapy Market
20.2.3 Major Product Offerings
20.2.4 Key Strengths
20.2.5 Key Strategies
20.2.6 Key Opportunities
20.3 Novartis
20.3.1 Business Overview
20.3.2 Major Product Offerings
20.3.3 Novartis in Global Cell and Gene Therapy
20.3.4 Key Strengths
20.3.5 Key Strategies
20.3.6 Key Opportunities
20.4 Organogenesis
20.4.1 Business Overview
20.4.2 Major Product Offerings
20.4.3 Key Strengths
20.4.4 Key Strategies
20.4.5 Key Opportunities
20.5 Amgen
20.5.1 Business Overview
20.5.2 Product Offerings
20.5.3 Amgen in the Global Cell and Gene Therapy Market
20.5.4 Key Strengths
20.5.5 Key Strategies
20.5.6 Key Opportunities
20.6 Osiris Therapeutics
20.6.1 Business Overview
20.6.2 Product Offerings
20.6.3 Osiris Therapeutics in the Global Cell and Gene Therapy Market
20.6.4 Key Strengths
20.6.5 Key Strategies
20.6.6 Key Opportunities
20.7 Dendreon
20.7.1 Business Overview
20.7.2 Product Offerings
20.7.3 Dendreon in The Global Cell and Gene Therapy Market
20.7.4 Key Strengths
20.7.5 Key Strategies
20.7.6 Key Opportunities
20.8 Vericel
20.8.1 Business Overview
20.8.2 Product Offerings
20.8.3 Vericel in the Global Cell and Gene Therapy Market
20.8.4 Key Strengths
20.8.5 Key Strategies
20.8.6 Key Opportunities

21 Other Prominent Vendors
21.1 Anterogen
21.1.1 Business Overview
21.1.2 Major Product Offerings
21.2 Tego Sciences
21.2.1 Business Overview
21.2.2 Major Product Offerings
21.3 Japan Tissue Engineering (J-TEC)
21.3.1 Business Overview
21.3.2 Major Product Offerings
21.4 JCR Pharmaceuticals
21.4.1 Business Overview
21.4.2 Major Product Offerings
21.5 Medipost
21.5.1 Business Overview
21.5.2 Major Product Offerings
21.6 MolMed
21.6.1 Business Overview
21.6.2 Major Product Offerings
21.7 Avita Medical
21.7.1 Business Overview
21.7.2 Major Product Offerings
21.8 CollPlant
21.8.1 Business Overview
21.8.2 Major Product Offerings
21.9 Corestem
21.9.1 Business Overview
21.10 Biosolution
21.10.1 Business Overview
21.10.2 Major Product Offerings
21.11 Stempeutics Research
21.11.1 Business Overview
21.11.2 Major Product Offerings
21.12 Orchard Therapeutics
21.12.1 Business Overview
21.12.2 Major Product Offerings
21.13 Takeda Pharmaceutical Company
21.13.1 Business Overview
21.13.2 Major Product Offerings
21.14 CHIESI Farmaceutici
21.14.1 Business Overview
21.14.2 Major Product Offerings
21.15 CO.DON
21.15.1 Business Overview
21.15.2 Major Product Offerings
21.16 AnGes
21.16.1 Business Overview
21.16.2 Major Product Offerings
21.17 GC Pharma
21.17.1 Business Overview
21.17.2 Major Product Offerings
21.18 JW CreaGene
21.18.1 Business Overview
21.18.2 Major Product Offerings
21.19 APAC Biotech
21.19.1 Business Overview
21.19.2 Major Product Offerings
21.20 Nipro
21.20.1 Business Overview
21.20.2 Major Product Offerings
21.21 Terumo
21.21.1 Business Overview
21.21.2 Major Product Offerings
21.22 Orthocell
21.22.1 Business Overview
21.22.2 Major Product Offerings
21.23 Bluebird Bio
21.23.1 Business Overview
21.23.2 Major Product Offerings

22 Report Summary
22.1 Key Takeaways
22.2 Strategic Recommendations
22.3 Quantitative Summary
22.3.1 By Product
22.3.2 By Application
22.3.3 By End-user
22.3.4 By Geography

23 Appendix
23.1 Abbreviations

List of Exhibits
Exhibit 1 Global Cell and Gene Therapy Market: Segmentation
Exhibit 2 Market Size Calculation Approach 2018
Exhibit 3 Important Events in the Development of Gene Therapy
Exhibit 4 Impact of Increased Pool of Patients with Various Diseases
Exhibit 5 Elderly Population in Select Countries 2018 (% share)
Exhibit 6 Impact of Product Launches and Approvals
Exhibit 7 Impact of Favorable Regulatory Support and Special Designations for Cell & Gene Therapy Products
Exhibit 8 Impact of Growing Demand for CAR T-cell Therapy Products
Exhibit 9 Yescarta and Kymriah Revenue 2018 ($ million)
Exhibit 10 Impact of High Cost of Cell and Gene Therapy Products
Exhibit 11 Selective Marketed Cell and Gene Therapy Products ($cost)
Exhibit 12 Impact of Manufacturing and Operational Challenges
Exhibit 13 Challenges Associated with Cell and Gene Therapy Products
Exhibit 14 Impact of Availability of Alternative Treatment Options and Withdrawal of Products
Exhibit 15 Impact of Increasing Strategic Acquisition Activities
Exhibit 16 Impact of Robust Cell and Gene Therapy Pipeline Products
Exhibit 17 Impact of Increasing Funding for Cell and Gene Therapy R&D Activities
Exhibit 18 Impact of Expanding Application of Cell and Gene Therapy Products
Exhibit 19 Global Cell and Gene Therapy Market: Overview
Exhibit 20 Global Cell and Gene Therapy Market 2018−2024 ($ million)
Exhibit 21 Global Cell and Gene Therapy Market: Segmentation by Geography 2018 & 2024 (% share)
Exhibit 22 Global Cell and Gene Therapy Market by Product Type 2018 & 2024 (% share)
Exhibit 23 Global Cell and Gene Therapy Market by Application 2018 & 2024($)
Exhibit 24 Global Cell and Gene Therapy Market by End User 2018 & 2024($)
Exhibit 25 Five Force Analysis 2018
Exhibit 26 Incremental Growth by Product 2018-2024
Exhibit 27 Global Cell & Gene Therapy Market Segmentation by Product
Exhibit 28 Global Cell and Gene Therapy Market by Product 2018 & 2024 (% share)
Exhibit 29 Global Cell and Gene Therapy Market by Product 2018−2024 ($ million)
Exhibit 30 Global Cell and Gene Therapy Market by Product 2018−2024 (% share)
Exhibit 31 Global Cell Therapy Market 2018−2024 ($ million)
Exhibit 32 Functioning of CAR T-cell Therapy
Exhibit 33 Global Gene Therapy Market 2018−2024 ($ million)
Exhibit 34 Incremental Growth by Application 2018-2024
Exhibit 35 Global Cell and Gene Therapy Market by Application
Exhibit 36 Global Cell and Gene Therapy Market by Application 2018 & 2024 (%)
Exhibit 37 Global Cell and Gene Therapy Market by Application 2018−2024 ($ million)
Exhibit 38 Global Cell and Gene Therapy Market by Application 2018−2024 (% share)
Exhibit 39 Global Cancer Incidence by Region 2018 (% share)
Exhibit 40 Global Cell and Gene Therapy Market by Oncology 2018−2024 ($ million)
Exhibit 41 Revenue of Major Cell and Gene Therapy Products for Cancer Treatment ($ million)
Exhibit 42 Global Cell and Gene Therapy Market by Dermatology 2018−2024 ($ million)
Exhibit 43 Global Cell and Gene Therapy Market by Musculoskeletal Disorders 2018−2024 ($ million)
Exhibit 44 Global Cell and Gene Therapy Market by Other Applications 2018−2024 ($ million)
Exhibit 45 Incremental Growth by End-user 2018-2024
Exhibit 46 Global Cell & Gene Therapy Market by End-user
Exhibit 47 Global Cell and Gene Therapy Market by End-Users 2018 & 2024 (% share)
Exhibit 48 Global Cell and Gene Therapy Market by End-Users 2018−2024 ($ million)
Exhibit 49 Global Cell and Gene Therapy Market by End-Users 2018−2024 (% share)
Exhibit 50 Global Cell and Gene Therapy Market by Hospitals 2018−2024 ($ million)
Exhibit 51 Global Cell and Gene Therapy Market by Wound Care Centers 2018−2024 ($ million)
Exhibit 52 Global Cell and Gene Therapy Market by Cancer Care Centers 2018−2024 ($ million)
Exhibit 53 Global Cell and Gene Therapy Market by ASCs 2018−2024 ($ million)
Exhibit 54 Global Cell and Gene Therapy Market by Other End-users 2018−2024 ($ million)
Exhibit 55 Incremental Growth by Geography 2018-2024
Exhibit 56 Global Cell & Gene Therapy Market by Region
Exhibit 57 Global Cell and Gene Therapy Market by Region 2018 & 2024 (%)
Exhibit 58 Global Cell and Gene Therapy Market by Region 2018−2024 ($ million)
Exhibit 59 Global Cell and Gene Therapy Market by Region 2018−2024 (%)
Exhibit 60 Cell and Gene Therapy Market in North America 2018–2024 ($ million)
Exhibit 61 Incremental Growth in North America 2018-2024
Exhibit 62 Estimated New Cases of Blood Cancer Types in US 2018 (% shares)
Exhibit 63 Cell and Gene Therapy Market in US 2018–2024 ($ million)
Exhibit 64 Cell and Gene Therapy Market in Canada 2018–2024 ($ million)
Exhibit 65 Cell and Gene Therapy Market in Europe 2018–2024 ($ million)
Exhibit 66 Incremental Growth in Europe 2018-2024
Exhibit 67 Cell and Gene Therapy Market in Germany 2018–2024 ($ million)
Exhibit 68 Cell and Gene Therapy Market in France 2018–2024 ($ million)
Exhibit 69 Cell and Gene Therapy Market in UK 2018–2024 ($ million)
Exhibit 70 Cell and Gene Therapy Market in Spain 2018–2024 ($ million)
Exhibit 71 Cell and Gene Therapy Market in Italy 2018–2024 ($ million)
Exhibit 72 Cell and Gene Therapy Market in APAC 2018–2024 ($ million)
Exhibit 73 Incremental Growth in APAC 2018-2024
Exhibit 74 Cell and Gene Therapy Market in Japan 2018–2024 ($ million)
Exhibit 75 Cell and Gene Therapy Market in China 2018–2024 ($ million)
Exhibit 76 Cell and Gene Therapy Market in South Korea 2018–2024 ($ million)
Exhibit 77 Cell and Gene Therapy Market in Australia 2018–2024 ($ million)
Exhibit 78 Cell and Gene Therapy Market in Latin America 2018–2024 ($ million)
Exhibit 79 Incremental Growth in Latin America 2018-2024
Exhibit 80 Cell and Gene Therapy Market in Brazil 2018–2024 ($ million)
Exhibit 81 Cell and Gene Therapy Market in Mexico 2018–2024 ($ million)
Exhibit 82 Cell and Gene Therapy Market in MEA 2018–2024 ($ million)
Exhibit 83 Incremental Growth in MEA 2018-2024
Exhibit 84 Cell and Gene Therapy Market in Turkey 2018–2024 ($ million)
Exhibit 85 Cell and Gene Therapy Market in Saudi Arabia 2018–2024 ($ million)
Exhibit 86 Cell and Gene Therapy Market in UAE 2018–2024 ($ million)
Exhibit 87 Global Gene Therapy Market: Vendors Market Shares 2018 (%)
Exhibit 88 Gilead Sciences Revenue 2016-2018 ($ billion)
Exhibit 89 Yescarta Revenue by Geography ($ million) in 2018
Exhibit 90 Spark Therapeutics Revenue 2018 ($ million)
Exhibit 91 Spark Therapeutics R&D Expenditure ($ million)
Exhibit 92 Novartis Revenue 2016-2018 ($ billion)
Exhibit 93 Novartis Revenue Breakdown by Business Units FY2018 (% share)
Exhibit 94 Novartis Revenue Breakdown by Geography FY2018 (% share)
Exhibit 95 Amgen Annual Revenue 2016-2018 ($ billion)
Exhibit 96 Amgen Revenue by Geography in 2018 (% share)
Exhibit 97 Osiris Therapeutics Annual Revenue 208-2016 ($ million)
Exhibit 98 Vericel Revenue 2016-2018 ($ million)
Exhibit 99 Vericel R&D Expenditure 2016-2018 ($ million)
Exhibit 100 Vericel Products Revenue Contribution FY2018 (%)

List of Tables
Table 1 Key Caveats
Table 2 Currency Conversion 2013−2018
Table 3 Worldwide Population Affected by Variety of Disease Conditions
Table 4 Global Cell and Gene Therapy Market: Recent Product Launches
Table 5 Revenue of major product Launched recently in the cell and gene therapy($Million)
Table 6 RMAT Designations Granted for Various Cell & Gene Therapy Products
Table 7 List of RMAT designated Investigational Cell & Gene Therapy Products
Table 8 CAR T-Cell Investigational Products
Table 9 Cost of KymriahinDifferent Regions
Table 10 Withdrawal of Cell and Gene Therapy Products
Table 11 Recent Strategic Acquisitions in Global Cell and Gene Therapy Market
Table 12 Investigational Cell and Gene Therapy Products
Table 13 Cell and Gene Therapy Products with Expanding Application
Table 14 Popular Commercial Cell Therapy Products
Table 15 Revenue of Popular Commercial Gene Therapy Products
Table 16 Approved Gene Therapy Products
Table 17 Global Cancer Incidence Rate by Cancer Type 2018
Table 18 Major Cell and Gene Therapy Products Available for Cancer Treatment
Table 19 Approved Cell and Gene Therapy Products for Rare Cardiovascular and other Diseases/Conditions
Table 20 Prominent Cancer Care Centers Around the World
Table 21 Major Cell Gene Therapy Products Approved in Europe
Table 22 Approved Cell and Gene Therapy Products in APAC
Table 23 Ranking of Vendors Offering Cell and Gene Therapy Products 2018
Table 24 Ranking of Vendors Offering Cell Therapy Products 2018
Table 25 Ranking of Vendors Offering Gene Therapy Products 2018
Table 26 Gilead Sciences: Product Offerings
Table 27 Spark Therapeutics: Product Offerings
Table 28 Novartis: Product Offerings
Table 29 Organogenesis: Product Offerings
Table 30 Amgen Corporation: Key Product Offerings
Table 31 Osiris Therapeutics: Key Product Offerings
Table 32 Dendreon: Key Product Offerings
Table 33 Vericel: Key Product Offerings
Table 34 Anterogen: Key Product Offerings
Table 35 Tego Sciences: Key Product Offerings
Table 36 Japan Tissue Engineering: Key Product Offerings
Table 37 JCR Pharmaceuticals: Key Product Offerings
Table 38 Medipost: Key Product Offerings
Table 39 MolMed: Product Offerings
Table 40 Avita Medical: Key Product Offerings
Table 41 CollPlant: Key Product Offerings
Table 42 CORESTEM R&D Pipeline Highlights (As of July 2018)
Table 43 Biosolution: Key Product Offerings
Table 44 Stempeutics Research: Key Product Offerings
Table 45 Orchard Therapeutics: Key Product Offerings
Table 46 Takeda Pharmaceutical Company: Key Product Offerings
Table 47 CHIESI Farmaceutici: Key Product Offerings
Table 48 CO.DON: Key Product Offerings
Table 49 AnGes: Key Product Offerings
Table 50 GC Pharma: Key Product Offerings
Table 51 JW CreaGene: Key Product Offerings
Table 52 APAC Biotech: Key Product Offerings
Table 53 Nipro: Key Product Offerings
Table 54 Terumo: Key Product Offerings
Table 55 Orthocell: Key Product Offerings
Table 56 Bluebird bio: Key Product Offerings
Table 57 Global Cell and Gene Therapy Market by Products ($million)
Table 58 Global Cell and Gene Therapy Market by Products (% share)
Table 59 Global Cell and Gene Therapy Market by Application ($ million)
Table 60 Global Cell and Gene Therapy Market by Application (% share)
Table 61 Global Cell and Gene Therapy Market by End User ($ millions)
Table 62 Global Cell and Gene Therapy Market by End User (% share)
Table 63 Global Cell and Gene Therapies Market by Geography ($ millions)
Table 64 Global Cell and Gene Therapy Market by Geography (% share)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Gilead Sciences
  • Spark Therapeutics
  • Novartis AG
  • Organogenesis
  • Amgen
  • Osiris Therapeutics
  • Dendreon
  • Vericel
  • Anterogen
  • Tego Sciences
  • Japan Tissue Engineering
  • JCR Pharmaceuticals
  • Medipost
  • MolMed
  • AVITA Medical
  • CollPlant
  • Corestem
  • Biosolution
  • Stempeutics Research
  • Orchard Therapeutics
  • Takeda Pharmaceutical Company
  • CHIESI Farmaceutici
  • CO.DON
  • AnGes
  • GC Pharma
  • JW CreaGene
  • APAC Biotech
  • Nipro Corp.
  • Terumo
  • Orthocell
  • Bluebird bio
Note: Product cover images may vary from those shown
5 of 5

Our research comprises a mix of primary and secondary research. The secondary research sources that are typically referred to include, but are not limited to, company websites, annual reports, financial reports, company pipeline charts, broker reports, investor presentations and SEC filings, journals and conferences, internal proprietary databases, news articles, press releases, and webcasts specific to the companies operating in any given market.

Primary research involves email interactions with the industry participants across major geographies. The participants who typically take part in such a process include, but are not limited to, CEOs, VPs, business development managers, market intelligence managers, and national sales managers. We primarily rely on internal research work and internal databases that we have populated over the years. We cross-verify our secondary research findings with the primary respondents participating in the study.



 

Loading
LOADING...

Adroll
adroll